Interassay Comparison With Digital Image Analysis of 4 Routine Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry Assays in Primary Breast Cancer and Its Metastasis.

Maaike Anna Hempenius¹, Mieke C Zwager², Jeppe Thagaard³, Lorian Slagter-Menkema⁴, Henk J Buikema², Ellis Barbé⁵, Michael A den Bakker⁶, Marjolein G J Heerema⁷, Elisabeth G E de Vries⁸, Carolina P Schröder⁹, Nils A 't Hart¹⁰, Bert van der Vegt²

¹Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: m.a.hempenius@umcg.nl.

²Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

³Visiopharm A/S, Horsholm, Denmark.

⁴Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Otolaryngology and Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

⁵Department of Pathology, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands.

⁶Department of Pathology, Maasstad Ziekenhuis, Rotterdam, the Netherlands.

⁷Pathologie Friesland, Leeuwarden, the Netherlands.

⁸Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

⁹Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

¹⁰Department of Pathology, Isala Hospital, Zwolle, the Netherlands.

PubMed DOI

Abstract

Trastuzumab-deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), improves overall survival in patients with breast cancer showing low or ultralow HER2 expression. Differences in HER2 test results have been reported between various HER2 assays and between primary tumors and metastases, but an objective comparison with incorporation of the new HER2-ultral…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.